| Literature DB >> 31724720 |
Carina Blomström-Lundqvist1, Vassil Traykov2, Paola Anna Erba3, Haran Burri4, Jens Cosedis Nielsen5, Maria Grazia Bongiorni6, Jeanne Poole7, Giuseppe Boriani8, Roberto Costa9, Jean-Claude Deharo10, Laurence M Epstein11, Laszlo Saghy12, Ulrika Snygg-Martin13, Christoph Starck14, Carlo Tascini15, Neil Strathmore16.
Abstract
Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially life-saving treatments for a number of cardiac conditions, but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infection, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased healthcare costs. Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well recognized. Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket antibiotic solutions, anti-bacterial envelopes, prolonged antibiotics post-implantation, and others. Guidance on whether to use novel device alternatives expected to be less prone to infections and novel oral anticoagulants is also limited, as are definitions on minimum quality requirements for centres and operators and volumes. Moreover, an international consensus document on management of CIED infections is lacking. The recognition of these issues, the dissemination of results from important randomized trials focusing on prevention of CIED infections, and observed divergences in managing device-related infections as found in an European Heart Rhythm Association worldwide survey, provided a strong incentive for a 2019 International State-of-the-art Consensus document on risk assessment, prevention, diagnosis, and treatment of CIED infections. © European Heart Rhythm Association 2019. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission of the Publishers. For Permissions, please email: journals.permissions@oup.com.Entities:
Keywords: Cardiac implantable electronic devices; Cardiac resynchronization therapy; EHRA consensus document; Endocarditis; Extraction; Implantable cardioverter-defibrillators; Infection; Leads; Microbiology; Pacemakers; Re-implantation
Mesh:
Year: 2020 PMID: 31724720 DOI: 10.1093/ejcts/ezz296
Source DB: PubMed Journal: Eur J Cardiothorac Surg ISSN: 1010-7940 Impact factor: 4.191